Univariate Cox regression analyses revealed that age, gender, and TP53 expression (TP53-exp) had no effect on prognosis, whereas TP53 mutations, cancer status, and treatment outcomes affected the prognosis of patients with LUAD (Fig. 8E and Table 4; Age, HR = 1.01 [95% CI, 0.994 to 1.02], P = 0.24; Gender, HR = 1.05 [95% CI, 0.78 to 1.4], P = 0.765; TP53-exp, HR = 0.921 [95% CI, 0.762 to 1.11], P = 0.392; TP53-WT, HR = 0.745 [95% CI, 0.556 to 0.998], P < 0.05; additional therapy, P < 0.05; cancer status, P < 0.05). This evidence concerns the gene TP53 and cancer.